Skip to main content
x

Recent articles

Gilead puts its Car-T money where its mouth is

KITE-753 is to enter pivotal development – head-to-head against Yescarta.

AACR 2026 – private biotechs score plenaries

Circle Pharma and Verismo feature in coveted sessions.

Pan-KRAS gets even more crowded

Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.

Like Lilly, Novartis bets against mutation specificity

The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.

AACR 2026 – one more shot for integrins

A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.

Henlius starts a pivotal journey to catch Pfizer

The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.